PLASMA MEMBRANE STIM1 AS A NEW THERAPEUTIC TARGET FOR SLE AND CLL

OUEST VALORISATION



20 Juin 2018

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

Chronic lymphocytic leukemia (CLL) is the leading cause of leukemia in Western countries. To date, no treatment including the novel therapies
targeting the B cell receptor (BCR) pathway (e.g.anti-CD20 monoclonal antibodies (mAb), BCR kinase inhibitors), offers a complete remission. It is
noteworthy that the rate of treatment interruptions and toxicity remain elevated for these patients. Systemic lupus erythematosus (SLE) is an
autoimmune disease, characterized by the presence of autoreactive lymphocytes and of antinuclear auto-antibodies (ANA). It is a multisystemic disease, with heterogenous clinical manifestations. SLE may affect all organs.


The invention relates to the use of the fraction of STIM1 localized to the plasma membrane as a therapeutic target in CLL and SLE by modulating its
presence or its activity.

Key benefits :

  • Presence of the marker solely on affected cells
  • Expression by the immune cells of the STIM1 protein at the plasma membrane
    facilitates the accessibility of this target
Download the offer Download the offer

Newsletter